ABSTRACT mGluR1 receptors are believed to play major roles in the pathophysiology of diseases such as anxiety and chronic pain and are being actively investigated as targets for drug development.
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INTRODUCTION
Glutamate is the major excitatory neurotransmitter in the central nervous system, it produces its excitatory effects by acting on two classes of cell surface receptors, ligand gated cation channels known as ionotropic glutamate receptors and G protein coupled receptors termed metabotropic glutamate receptors (1) . Metabotropic glutamate receptors form a family of eight subtypes (mGluR1-8) which on the basis of structural homology, pharmacology and signal transduction mechanisms are subdivided into three groups (2) . Group I receptors (mGluR1 and mGluR5) usually act postsynaptically to increase neuronal excitability (3) . Excessive glutamatergic neurotransmission has been shown to underlie many CNS diseases and to play an important role in the pathophysiology of diseases such as depression, anxiety, and chronic pain, which represent key areas of interest for drug development. Accordingly, mGluR group I antagonists could represent useful agents for the treatment of these conditions. Indeed, in preclinical models, mGluR I antagonists have been shown to be very effective agents in the treatment of prolonged and chronic pain (4) (5) (6) and to possess anxiolytic activity (7, 8) . Recent data suggests that mGluR1
antagonists may also be useful therapeutic agents for treating drug dependence (9) and depression (10) . However, the involvement of mGluR1 in human CNS disorders has yet to be demonstrated, it is therefore important to carry out clinical proof of concept studies to understand the functions of mGluR1 in man. As a prelude to this type of activity it is important to understand the genetic variation within this receptor gene among human populations and within different ethnic groups.
Single nucleotide polymorphisms (SNPs), substitutions of a novel nucleotide for the wild type nucleotide within genomic DNA are the most common type of genetic variation and occur at a frequency of greater than 1% in the general population (11). Within the coding region of a gene, non synonymous SNPs, those that change the encoded amino acid sequence, can profoundly effect protein folding and disrupt post translational modifications (12). As far as GPCRs are concerned, there are a number of reports which show that non synonymous SNPS may also alter the normal functioning of the receptor by disrupting ligand-receptor binding (13) or altering the normal coupling to G proteins (14, 15). In some cases, SNPs may lead to increased disease susceptibility or yield variable responses to therapeutic agents. Therefore, evaluating the pharmacogenetics of disease-related targets is an important step in the drug development process.
The current study reveals the frequency of polymorphisms in the human mGluR1 gene and pharmacologically characterizes the very frequent P993S receptor variant. Despite the fact that eight non synonymous SNPs were identified, most were very rare and only the P993S variant was present at a frequency of greater than 5% in both populations. We have previously described the use of an inducible system, the Ecdysone system, to functionally express representative mGluR subtypes (16). Expressing the WT and S993 mGluR1 variants in this system allowed us to tightly regulate gene expression, so that we were able to express the two forms of the receptor at almost Page 4 of 24 A c c e p t e d M a n u s c r i p t 4 identical expression levels facilitating the functional analysis of the receptor variants. It has previously been demonstrated that non competitive antagonist compounds bind to the same binding pocket made from transmembrane helices IV-VII (17). All of the mGluR1 selective antagonists tested displayed similar potencies and affinities at the two receptor variants, it is therefore unlikely that the identified genetic variations would significantly modify the effectiveness of mGluR1 antagonists in man.
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MATERIALS AND METHODS

2.1.Compounds
Agonists, DHPG (3,5- 
Antagonists, JNJ16259685, (3,4-dihydro-2H-pyrano [2, 3] b-quinolinyl-7-yl)(cis-4-methoxycyclohexyl) methanone, LY456236, (4-methoxy-phenyl)-(6-methoxy-quinazolin-4-yl)-amine hydrochloride; All agonists and antagonists were purchased from Tocris Cookson (Bristol, UK), except for SCH1041222 which was synthesised by Schering Plough. Compounds were dissolved in HBSS or DMSO depending on their solubility. The final concentration of DMSO in all samples was compensated.
2.2.Research Subjects
To identify SNPs, the mGluR1 gene was sequenced from anonymous Caucasian (n=47) and African American (n=46) individuals. Genomic DNA samples were obtained from the Caucasian and African American human variation panels collected from the Human Genetic Cell Repository of the National Institute for General Medical Sciences (Coriell Cell Repository; Camden, NJ, USA). All samples came from individuals who provided informed consent to be part of the DNA polymorphism Discovery Resource. Information on geographic origin and gender was collected for each individual in order to assemble the DNA polymorphism Discovery Resource, but all identifying and phenotypic information has been removed from the individual samples.
Polymerase chain reaction
The general strategy for SNP discovery is as previously described (18) TTACAGGGTGGAAGAGCTTTGCTTG 3' (3561-3588), the 5' and 3' fragments were cloned into pCRScript and fully sequenced on both DNA strands. After sequence confirmation the amplified products were joined together using the restriction enzyme Sac1 which has a single site within the mGluR1a coding sequence at nucleotide position 1890. The entire coding sequence was subcloned into pCRscript and the junction region was sequenced. To create the expression construct, the mGluR1 coding sequence was amplified using the following primers, Fwd 5'
gCggCCgCggATCCTTCCCCCTTACAgggTggAAgAgCTTTgCTTgTAgTCCC which contain an EcoR1 site and a full kozak sequence (forward primer) and a Not1 site (Reverse primer). The mGluR1a coding sequence was sub-cloned into the expression vector pIND (Invitrogen, Paisley UK) as an EcoR1-Not1 fragment, the construct was fully sequenced on both DNA strands.
Creation of polymorphic variant
The following primer pair was used to amplify a 1260 bp fragment at the 3' end of the mGluR1a coding sequence from human hippocampal c-DNA, the amplified product extended from base pair was made by replacing the Nde1-Not1 restriction fragment from pINDP993 with the equivalent fragment from plasmid pCRScript-S993. The expression construct was completely sequenced in the region that had undergone restriction fragment swapping to confirm that only the intended mutation had been introduced.
Isolation of clonal cell lines
The HEK-293 EcR cell line (Invitrogen, Paisley UK), stably expressing the heterodimeric ecdysone receptor from the pVgRXR plasmid, was maintained in DMEM high glucose, supplemented with 10% foetal bovine serum (FBS), Pen/Strep, Glutamax™ (Invitrogen, Paisley UK) and 400µg/ml Zeocin™ (Invitrogen, Paisley UK) at 37°C, in an atmosphere containing 5% CO 2 . Stable transfections with mGluR1a coding vectors, pINDP993 and pINDS993 were performed using Calcium Phosphate according to standard protocols. Stably transfected clones were obtained after selection with 550µg/ml Geneticin ® (Invitrogen, Paisley UK). During the induction of the receptor, cells were maintained in essentially the same culture medium except for the substitution of 5% dialysed serum and the addition of 3U GPT (Sigma) and 5mM sodium pyruvate.
Binding
Saturation binding experiments to membrane preparations were carried out in a total volume of compound and 375nM WT and 264nM S993 for the LY456236 compound were determined (Figure 2 a and b) . We also determined the potency of all of these non competitive antagonist compounds in functional calcium assays, quisqualate-induced Ca i 2+ release was tested in the presence or absence of LY456236, JNJ16259685 and SCH1041222 (Fig 3) . When an agonist concentration corresponding to an EC 80 value was utilised to stimulate the receptor, the addition of these reference antagonists resulted in a concentration-dependent inhibition of quisqualate elicited calcium signal with calculated IC 50 values of 267nM LY456236, 2.3nM JNJ16259685 and 4.7nM
SCH1041222 for the WT cell line and 445nM LY456236, 3.1nM JNJ16259685 and 5.2nM
SCH1041222 for the S993 variant ( Table 3) . Here again we did not observe significant differences in the potencies of these compounds at the two receptor variants. The focus of the present study was to determine if the S993 polymorphism had an effect on the affinity or potency of antagonist compounds. However, given the fact that the polymorphic residue resides in the C terminal tail of the protein, it could effect G protein/receptor coupling we therefore performed functional calcium assays with a number of agonist compounds. Again there were no significant differences, in either the potency or the efficacy of any of the compounds tested, ( Fig 4 for curves and table 3 ) .
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DISCUSSION
It is widely recognised that different patients respond in different ways
Figure Legends
